Shanghai Fosun Pharmaceutical Secures Regulatory Nod for Expanded Use of Lung Cancer Drug

Stock News09-03 16:26

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its majority-owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the National Medical Products Administration for a new indication of its drug, Lumvatinib tablets (brand name: Fumaining, project code: FCN-159).

The newly approved indication covers adult patients with neurofibromatosis type 1 (NF1) who present with symptomatic, inoperable plexiform neurofibromas (PN). This marks a significant expansion of the drug's approved uses.

Lumvatinib is an innovative small-molecule chemical drug developed in-house by the group, functioning as a selective inhibitor of MEK1/2. The approval of this additional indication is expected to offer a new therapeutic option for patients suffering from related rare tumors within China, while also strengthening the drug's competitive position in the market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168391109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 16:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168391109","market":"fut","top_or_hot":-1,"title":"Shanghai Fosun Pharmaceutical Secures Regulatory Nod for Expanded Use of Lung Cancer Drug","media":"Stock News","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its majority-owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the National Medical Products Administration for a new indication of its drug, Lumvatinib tablets (brand name: Fumaining, project code: FCN-159).<br><br>The newly approved indication covers adult patients with neurofibromatosis type 1 (NF1) who present with symptomatic, inoperable plexiform neurofibromas (PN). This marks a significant expansion of the drug's approved uses.<br><br>Lumvatinib is an innovative small-molecule chemical drug developed in-house by the group, functioning as a selective inhibitor of MEK1/2. The approval of this additional indication is expected to offer a new therapeutic option for patients suffering from related rare tumors within China, while also strengthening the drug's competitive position in the market.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fosun Pharmaceutical Secures Regulatory Nod for Expanded Use of Lung Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fosun Pharmaceutical Secures Regulatory Nod for Expanded Use of Lung Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-03 16:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its majority-owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the National Medical Products Administration for a new indication of its drug, Lumvatinib tablets (brand name: Fumaining, project code: FCN-159).<br><br>The newly approved indication covers adult patients with neurofibromatosis type 1 (NF1) who present with symptomatic, inoperable plexiform neurofibromas (PN). This marks a significant expansion of the drug's approved uses.<br><br>Lumvatinib is an innovative small-molecule chemical drug developed in-house by the group, functioning as a selective inhibitor of MEK1/2. The approval of this additional indication is expected to offer a new therapeutic option for patients suffering from related rare tumors within China, while also strengthening the drug's competitive position in the market.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"","article_id":"1168391109","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168391109","pubTimestamp":1788423987,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its majority-owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0012":"证金概念","BK0183":"MSCI概念","BK1593":"医美概念股","BK0196":"行业龙头","02196":"复星医药","BK0175":"白马股","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK1191":"制药","BK0096":"民营医院","BK0188":"融资融券","BK1515":"抗疫概念"},"translate_title":"上海复星医药因扩大肺癌药物使用获得监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its majority-owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., recently received approval from the National Medical Products Administration for a new indication of its drug, Lumvatinib tablets (brand name: Fumaining, project code: FCN-159).The newly approved indication covers adult patients with neurofibromatosis type 1 (NF1) who present with symptomatic, inoperable plexiform neurofibromas (PN). This marks a significant expansion of the drug's approved uses.Lumvatinib is an innovative small-molecule chemical drug developed in-house by the group, functioning as a selective inhibitor of MEK1/2. The approval of this additional indication is expected to offer a new therapeutic option for patients suffering from related rare tumors within China, while also strengthening the drug's competitive position in the market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168391109","isCrawlerRequest":true}